CDKN2A Deletion Predicts Risk of Venous Thromboembolism in Patients With Glioblastoma

0
40


Among patients with glioblastoma, the risk of venous thromboembolism (VTE) appears to be higher in those with CDKN2A deletion, according to research presented at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress. These results may help to identify patients with glioblastoma who could benefit from thromboprophylaxis.

While a link between VTE risk and glioblastoma has previously been established, no genetic risk factors have been established. There is, however, some evidence that underlying genetic risk factors may play a role.

For this retrospective cohort study, researchers attempted to determine whether any genetic aberrations predict the likelihood of VTE among patients with glioblastoma. The researchers evaluated next-generation sequencing and VTE data collected between 2017 and 2020. The tumor mutational status of ATRX, BRAF, CIC, FUBP1, H3F3A, IDH1, IDH2, PIK3CA, PTEN, and TP53, and the amplification or deletion status of BRAF, CDKN2A, EGFR, NOTCH1, and PTEN, had previously been established for diagnostic purposes.


Continue Reading

Overall, data from 341 patients were included. In the overall cohort, 215 patients had died by time of analysis, and 37 had been lost during the follow-up period.

A total of 26 patients were diagnosed with a VTE over the study period. Of the genes analyzed, TP53 mutation (P =.153), EGFR amplification (P =.315), PIK3CA mutation (P =.328), PTEN mutation or deletion (P =.656), ATRX mutation (P =.518), and IDH1 mutation (P =.991) showed no significant relationship with VTE incidence or risk of death.

CDKN2A deletion did, however, significantly predict VTE (HR, 2.65; P =.018). A competing risk analysis suggested, furthermore, that the 1-year VTE incidence was 12.7% in patients with CDKN2A deletion vs 5.2% in patients with the gene’s wild-type (P =.013). CDKN2A deletion did not, however, predict risk of death.

“This study demonstrates that CDKN2A deletion is associated with VTE in glioblastoma patients,” the authors wrote. “Therefore, CDKN2A mutational status may be a promising predictor to identify patients with glioblastoma at high risk of VTE, who may benefit from thromboprophylaxis.”

Reference

Kapteijn MY, Kaptein FH, Stals MA, et al. CDKN2A mutational status is associated with venous thromboembolism in patients with glioblastoma. Paper presented at: International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress; July 17-21, 2021; virtual. Abstract OC 30.3.

This article originally appeared on Hematology Advisor



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here